Your AI-Trained Oncology Knowledge Connection!
Chih-Yi (Andy) Liao, MD, discusses the focus of each presentation at the webinar, which centered on optimizing therapy in advanced pancreatic cancer, the contemporary use of surgery and systemic therapy in NETs, multidisciplinary approaches to hepatocellular carcinoma, and the evolving role of liver transplant and systemic therapy.
Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.
Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.
Peter Riedell, MD, discusses the effects of time to relapse on outcomes in mantle cell lymphoma.
Christine Bestvina, MD, discusses the emerging role of neoadjuvant chemoimmunotherapy in lung cancer.
Christine Bestvina, MD, discusses challenges with interpreting molecular reports in lung cancer.
Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.
Daniel Catenacci, MD, discusses recent updates in gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.
Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.
Peter Riedell, MD, discusses the importance of identifying early relapse in patients with high-risk mantle cell lymphoma.
“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.
Peter Riedell, MD, discusses the rationale for a study in mantle cell lymphoma, the clinical implications of the findings, and unanswered questions that future research efforts should aim to answer.
Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.
Michael R. Charlton, MD, MBBS, discusses the interaction between liver disease and hepatocellular carcinoma.
Marina Chiara Garassino, MD, discusses key safety protocols that were initiated for patients with cancer in Italy during the COVID-19 pandemic.
Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.
Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.
Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.
Olwen Hahn, MD, discusses future research directions with tucatinib (Tukysa) in the treatment of patients with breast cancer.
Michael R. Charlton, MD, MBBS, discusses the effects of the COVID-19 pandemic on hepatocellular carcinoma.
Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.
Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.
Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.
Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.
Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.
Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.
Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.
Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.
This week we have collaborated with The University of Chicago Medicine to highlight important topics facing oncologists today. Join us Saturday, May 16, 2020 at 11 AM EST.
